Skip to content
Search

Latest Stories

Submit Guest Post

Shares in UK bus operator Go-Ahead surge on global takeover

UK transport giant Go-Ahead saw its share price surge Tuesday after agreeing to a takeover from a global consortium.

Shares in UK bus operator Go-Ahead surge on global takeover

Shares in Go-Ahead, which operates London's famous red buses on behalf of the capital's transport authority, jumped 14 percent to £15.50 in late morning deals.

Go-Ahead revealed Monday that it would recommend a consortium takeover from Australian peer Kinetic and Spanish infrastructure investor Globalvia, who are both backed by a Canadian pension fund.

The cash bid, pitched at £15 per share including a special dividend, is worth £650 million ($790 million).

"This is a compelling offer which combines an attractive valuation for shareholders with bright prospects for Go-Ahead's operations and colleagues around the world," said group chief executive Christian Schreyer.

He noted that the group would be "part of a truly global mass transit platform (that) will yield exciting opportunities".

Kinetic and Globalvia have committed "to invest in the decarbonisation and digitalisation of" Go-Ahead, added Schreyer.

The UK company specialises in bus and coach transport in Britain, Ireland, Germany, Norway, Singapore and Sweden, employing more than 27,000 people worldwide.

(AFP)

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

cervical -cancer-hpv-vaccine

HPV is the most common sexually transmitted infection

Photo for representation: iStock

HPV vaccine reduces cervical cancer deaths to near zero, study finds

Highlights

  • No women aged 20–24 died from cervical cancer in England between 2020 and 2024
  • HPV vaccination is estimated to have prevented nearly 200 deaths among young women
  • Study provides first direct evidence linking HPV vaccination to reduced cervical cancer mortality
  • Vaccine introduced for girls in 2008 in the UK
  • Researchers say higher vaccination uptake is needed to protect future gains

THE HPV vaccine for cervical cancer has reduced the risk of dying from the disease before the age of 30 in England to almost zero, the first study of its kind showed on Thursday (18).

Keep ReadingShow less